1130 related articles for article (PubMed ID: 32708317)
61. Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease.
Bondar C; Ormazabal M; Crivaro A; Ferreyra-Compagnucci M; Delpino MV; Rozenfeld PA; Mucci JM
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098793
[TBL] [Abstract][Full Text] [Related]
62. High mobility group box 1 protein regulates osteoclastogenesis through direct actions on osteocytes and osteoclasts in vitro.
Davis HM; Valdez S; Gomez L; Malicky P; White FA; Subler MA; Windle JJ; Bidwell JP; Bruzzaniti A; Plotkin LI
J Cell Biochem; 2019 Oct; 120(10):16741-16749. PubMed ID: 31106449
[TBL] [Abstract][Full Text] [Related]
63. RANKL subcellular trafficking and regulatory mechanisms in osteocytes.
Honma M; Ikebuchi Y; Kariya Y; Hayashi M; Hayashi N; Aoki S; Suzuki H
J Bone Miner Res; 2013 Sep; 28(9):1936-49. PubMed ID: 23529793
[TBL] [Abstract][Full Text] [Related]
64. Ablation of p38α MAPK Signaling in Osteoblast Lineage Cells Protects Mice From Bone Loss Induced by Estrogen Deficiency.
Thouverey C; Caverzasio J
Endocrinology; 2015 Dec; 156(12):4377-87. PubMed ID: 26441240
[TBL] [Abstract][Full Text] [Related]
65. Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling.
Liu C; Cao Z; Zhang W; Tickner J; Qiu H; Wang C; Chen K; Wang Z; Tan R; Dong S; Xu J
J Cell Physiol; 2018 Nov; 233(11):8971-8983. PubMed ID: 29904917
[TBL] [Abstract][Full Text] [Related]
66. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
[TBL] [Abstract][Full Text] [Related]
67. Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice.
Liu W; Wang Z; Yang J; Wang Y; Li K; Huang B; Yan B; Wang T; Li M; Zou Z; Yang J; Xiao G; Cui ZK; Liu A; Bai X
Open Biol; 2019 May; 9(5):180262. PubMed ID: 31088250
[TBL] [Abstract][Full Text] [Related]
68. Promising bone-related therapeutic targets for rheumatoid arthritis.
Choi Y; Arron JR; Townsend MJ
Nat Rev Rheumatol; 2009 Oct; 5(10):543-8. PubMed ID: 19798028
[TBL] [Abstract][Full Text] [Related]
69. Role of osteocytes in multiple myeloma bone disease.
Delgado-Calle J; Bellido T; Roodman GD
Curr Opin Support Palliat Care; 2014 Dec; 8(4):407-13. PubMed ID: 25289928
[TBL] [Abstract][Full Text] [Related]
70. Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency.
Xiong J; Piemontese M; Thostenson JD; Weinstein RS; Manolagas SC; O'Brien CA
Bone; 2014 Sep; 66():146-54. PubMed ID: 24933342
[TBL] [Abstract][Full Text] [Related]
71. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands.
Horowitz MC; Xi Y; Wilson K; Kacena MA
Cytokine Growth Factor Rev; 2001 Mar; 12(1):9-18. PubMed ID: 11312114
[TBL] [Abstract][Full Text] [Related]
72. Activation of mTORC1 in B Lymphocytes Promotes Osteoclast Formation via Regulation of β-Catenin and RANKL/OPG.
Xu S; Zhang Y; Liu B; Li K; Huang B; Yan B; Zhang Z; Liang K; Jia C; Lin J; Zeng C; Cai D; Jin D; Jiang Y; Bai X
J Bone Miner Res; 2016 Jul; 31(7):1320-33. PubMed ID: 26825871
[TBL] [Abstract][Full Text] [Related]
73. Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice.
Weinstein RS; O'Brien CA; Almeida M; Zhao H; Roberson PK; Jilka RL; Manolagas SC
Endocrinology; 2011 Sep; 152(9):3323-31. PubMed ID: 21771887
[TBL] [Abstract][Full Text] [Related]
74. Lenalidomide regulates osteocytes fate and related osteoclastogenesis via IL-1β/NF-κB/RANKL signaling.
Qu X; Mei J; Yu Z; Zhai Z; Qiao H; Dai K
Biochem Biophys Res Commun; 2018 Jun; 501(2):547-555. PubMed ID: 29746861
[TBL] [Abstract][Full Text] [Related]
75. Mechanisms involved in normal and pathological osteoclastogenesis.
Park-Min KH
Cell Mol Life Sci; 2018 Jul; 75(14):2519-2528. PubMed ID: 29670999
[TBL] [Abstract][Full Text] [Related]
76. Tumor necrosis factor-α antagonist diminishes osteocytic RANKL and sclerostin expression in diabetes rats with periodontitis.
Kim JH; Kim AR; Choi YH; Jang S; Woo GH; Cha JH; Bak EJ; Yoo YJ
PLoS One; 2017; 12(12):e0189702. PubMed ID: 29240821
[TBL] [Abstract][Full Text] [Related]
77. A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice.
Kalyanaraman H; Ramdani G; Joshua J; Schall N; Boss GR; Cory E; Sah RL; Casteel DE; Pilz RB
J Bone Miner Res; 2017 Jan; 32(1):46-59. PubMed ID: 27391172
[TBL] [Abstract][Full Text] [Related]
78. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
79. The polymethoxy flavonoid sudachitin suppresses inflammatory bone destruction by directly inhibiting osteoclastogenesis due to reduced ROS production and MAPK activation in osteoclast precursors.
Ohyama Y; Ito J; Kitano VJ; Shimada J; Hakeda Y
PLoS One; 2018; 13(1):e0191192. PubMed ID: 29342179
[TBL] [Abstract][Full Text] [Related]
80. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
